[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhCFT2cb9i9nY5eaBk8cj6Ee2txbG8tF0Ku1LUjFsiU8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"Herlev Hospital",[4],199,false,23,3,647244,0,144,[14,17,20,22,24,26,28,31],{"name":15,"count":16},"Stroke",6,{"name":18,"count":19},"Neuromuscular Blockade",5,{"name":21,"count":19},"Prostate Cancer",{"name":23,"count":19},"Pancreatic Cancer",{"name":25,"count":19},"Pain",{"name":27,"count":19},"Melanoma",{"name":29,"count":30},"Depression",4,{"name":32,"count":30},"Malnutrition",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,99,145,168,199,217,242,268,294,319,345,372,390,415,441,502,532,581,603,628,652,679,697,715,741,766,791,809,835,853,879,897,921,939,964,988,1010,1034,1060,1083,1107,1135,1157,1181,1205,1238,1261,1286,1310,1334,1357,1382,1400,1423,1449,1473,1498],{"intervention":43,"totalTrials":30,"cells":44},"Rocuronium",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":97},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[55,70,80,89],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":68},"NCT02079337","Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery","COMPLETED",[39],"2014-04","2013-11",14,[64,65,66,18,67],"Surgical Conditions","Rating Scales","Laparoscopy","Pneumoperitoneum",[43,69],"sugammadex",{"nctId":71,"briefTitle":72,"status":58,"phases":73,"primaryCompletion":74,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":79},"NCT01722097","Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure",[39],"2014-03","2014-07","2012-11",110,[18,25,66],[43],{"nctId":81,"briefTitle":82,"status":58,"phases":83,"primaryCompletion":76,"completion":76,"start":84,"enrollment":85,"conditions":86,"interventions":88},"NCT01523886","The Muscle Relaxation-study",[39],"2012-03",49,[87],"Cholecystectomy, Laparoscopic",[43,43],{"nctId":90,"briefTitle":91,"status":58,"phases":92,"primaryCompletion":60,"completion":60,"start":93,"enrollment":62,"conditions":94,"interventions":95},"NCT01933425","Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade",[39],"2013-08",[18],[96,69],"rocuronium",{"trials":98,"activeCount":11},[],{"intervention":100,"totalTrials":9,"cells":101},"Melatonin",{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":115,"PHASE3":117,"PHASE4":130,"NA":143},{"trials":103,"activeCount":11},[],{"trials":105,"activeCount":11},[106],{"nctId":107,"briefTitle":108,"status":58,"phases":109,"primaryCompletion":110,"completion":93,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT01873430","The Sun Protective Effect of Melatonin",[36],"2013-05",22,[113],"Sunburn",[100],{"trials":116,"activeCount":11},[],{"trials":118,"activeCount":11},[119],{"nctId":120,"briefTitle":121,"status":58,"phases":122,"primaryCompletion":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT02386319","Anxiolytic and Analgesic Effects of Melatonin",[38],"2021-03","2021-04","2016-08",36,[128],"Anxiety",[100],{"trials":131,"activeCount":11},[132],{"nctId":133,"briefTitle":134,"status":58,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},"NCT01087359","Antiinflammatoric and Antioxidative Effect of Melatonin in Human Endotoxaemia",[39],"2011-01","2011-02","2010-06",12,[141],"Human Endotoxaemia",[100],{"trials":144,"activeCount":11},[],{"intervention":69,"totalTrials":146,"cells":147},2,{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":166},{"trials":149,"activeCount":11},[],{"trials":151,"activeCount":11},[],{"trials":153,"activeCount":11},[],{"trials":155,"activeCount":11},[],{"trials":157,"activeCount":11},[158,162],{"nctId":56,"briefTitle":57,"status":58,"phases":159,"primaryCompletion":60,"completion":60,"start":61,"enrollment":62,"conditions":160,"interventions":161},[39],[64,65,66,18,67],[43,69],{"nctId":90,"briefTitle":91,"status":58,"phases":163,"primaryCompletion":60,"completion":60,"start":93,"enrollment":62,"conditions":164,"interventions":165},[39],[18],[96,69],{"trials":167,"activeCount":11},[],{"intervention":169,"totalTrials":170,"cells":171},"Dalteparin Prefilled Syringe",1,{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":197},{"trials":173,"activeCount":11},[],{"trials":175,"activeCount":11},[],{"trials":177,"activeCount":11},[],{"trials":179,"activeCount":11},[],{"trials":181,"activeCount":11},[182],{"nctId":183,"briefTitle":184,"status":185,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":195},"NCT06020560","Study of Low Molecular Weight Heparins","UNKNOWN",[39],"2025-03-23","2023-03-23",65000,[191,192,193,194],"Anticoagulant","Venous Thromboembolism","Prophylaxis","Treatment",[169,196],"Tinzaparin profiled syringe",{"trials":198,"activeCount":11},[],{"intervention":196,"totalTrials":170,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":11},[],{"trials":204,"activeCount":11},[],{"trials":206,"activeCount":11},[],{"trials":208,"activeCount":11},[],{"trials":210,"activeCount":11},[211],{"nctId":183,"briefTitle":184,"status":185,"phases":212,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":213,"interventions":214},[39],[191,192,193,194],[169,196],{"trials":216,"activeCount":11},[],{"intervention":218,"totalTrials":170,"cells":219},"Rocuronium and Sugammadex",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":240},{"trials":221,"activeCount":11},[],{"trials":223,"activeCount":11},[],{"trials":225,"activeCount":11},[],{"trials":227,"activeCount":11},[],{"trials":229,"activeCount":11},[230],{"nctId":231,"briefTitle":232,"status":58,"phases":233,"primaryCompletion":234,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT02247466","Optimizing Surgical Conditions During Laparoscopic Herniotomy With Deep Neuromuscular Blockade",[39],"2017-02-23","2015-02",37,[238],"Laparoscopic Herniotomy",[218],{"trials":241,"activeCount":11},[],{"intervention":243,"totalTrials":170,"cells":244},"Triptorelin",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":266},{"trials":246,"activeCount":11},[],{"trials":248,"activeCount":11},[],{"trials":250,"activeCount":11},[],{"trials":252,"activeCount":11},[],{"trials":254,"activeCount":11},[255],{"nctId":256,"briefTitle":257,"status":58,"phases":258,"primaryCompletion":259,"completion":259,"start":60,"enrollment":260,"conditions":261,"interventions":265},"NCT02102646","MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism",[39],"2015-10",31,[21,262,263,264],"Metabolic Syndrome","Hypogonadism","Fatty Liver",[243],{"trials":267,"activeCount":11},[],{"intervention":269,"totalTrials":170,"cells":270},"Solu-medrol 125 mg",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":292},{"trials":272,"activeCount":11},[],{"trials":274,"activeCount":11},[],{"trials":276,"activeCount":11},[],{"trials":278,"activeCount":11},[],{"trials":280,"activeCount":11},[281],{"nctId":282,"briefTitle":283,"status":185,"phases":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":291},"NCT00307606","Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma",[39],"2007-12","2005-12",40,[289,290],"Breast Neoplasms","Mastectomy",[269],{"trials":293,"activeCount":11},[],{"intervention":295,"totalTrials":170,"cells":296},"Ropivacaine block",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":317},{"trials":298,"activeCount":11},[],{"trials":300,"activeCount":11},[],{"trials":302,"activeCount":11},[],{"trials":304,"activeCount":11},[],{"trials":306,"activeCount":11},[307],{"nctId":308,"briefTitle":309,"status":310,"phases":311,"primaryCompletion":312,"completion":313,"start":312,"enrollment":11,"conditions":314,"interventions":316},"NCT01923623","The Effect of Nerve Blockades in Addition to General Anesthesia in Surgical Fixation of Ankle Fractures.","WITHDRAWN",[39],"2013-07-01","2013-07-31",[315],"Ankle Fracture in Need of Surgical Fixation",[295],{"trials":318,"activeCount":11},[],{"intervention":320,"totalTrials":170,"cells":321},"Candesartan and enalapril",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":343},{"trials":323,"activeCount":11},[],{"trials":325,"activeCount":11},[],{"trials":327,"activeCount":11},[],{"trials":329,"activeCount":11},[],{"trials":331,"activeCount":11},[332],{"nctId":333,"briefTitle":334,"status":185,"phases":335,"start":336,"enrollment":337,"conditions":338,"interventions":341},"NCT00235287","Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease",[39],"2005-09",60,[339,340],"Kidney Failure, Chronic","Cardiovascular Diseases",[320,342,342,342],"candesartan and enalapril",{"trials":344,"activeCount":11},[],{"intervention":346,"totalTrials":170,"cells":347},"Group STANDARD: Rocuronium 0.6 mg\u002Fkg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).",{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":356,"NA":370},{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"trials":353,"activeCount":11},[],{"trials":355,"activeCount":11},[],{"trials":357,"activeCount":11},[358],{"nctId":359,"briefTitle":360,"status":58,"phases":361,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":368},"NCT02140593","The Laparotomy Study",[39],"2016-05","2016-06","2014-09",128,[367],"Gastrointestinal Cancer",[346,369],"Group DEEP: Rocuronium 0.6 mg\u002Fkg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.",{"trials":371,"activeCount":11},[],{"intervention":369,"totalTrials":170,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":388},{"trials":375,"activeCount":11},[],{"trials":377,"activeCount":11},[],{"trials":379,"activeCount":11},[],{"trials":381,"activeCount":11},[],{"trials":383,"activeCount":11},[384],{"nctId":359,"briefTitle":360,"status":58,"phases":385,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":386,"interventions":387},[39],[367],[346,369],{"trials":389,"activeCount":11},[],{"intervention":391,"totalTrials":170,"cells":392},"Eplerenone",{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":413},{"trials":394,"activeCount":11},[],{"trials":396,"activeCount":11},[],{"trials":398,"activeCount":11},[],{"trials":400,"activeCount":11},[],{"trials":402,"activeCount":11},[403],{"nctId":404,"briefTitle":405,"status":58,"phases":406,"primaryCompletion":407,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT02809963","Mineralocorticoid Receptor Antagonists in Type 2 Diabetes",[39],"2017-11","2015-11",140,[411],"Diabetes Type 2",[391],{"trials":414,"activeCount":11},[],{"intervention":416,"totalTrials":170,"cells":417},"modafinil",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":437,"NA":439},{"trials":419,"activeCount":11},[],{"trials":421,"activeCount":11},[],{"trials":423,"activeCount":11},[],{"trials":425,"activeCount":11},[426],{"nctId":427,"briefTitle":428,"status":429,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT01800097","Treatment of Post Stroke Fatigue With a Wakefulness Promoting Agent","TERMINATED",[38],"2015-03","2012-10",41,[15,435],"Post Stroke Fatigue",[416],{"trials":438,"activeCount":11},[],{"trials":440,"activeCount":11},[],{"intervention":442,"totalTrials":30,"cells":443},"Nivolumab",{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":445,"activeCount":11},[],{"trials":447,"activeCount":11},[],{"trials":449,"activeCount":11},[450,463,473,483],{"nctId":451,"briefTitle":452,"status":58,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":461},"NCT02866383","Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients",[37],"2022-01-05","2022-11-30","2016-11",160,[459,460],"Metastatic Pancreatic Cancer","Metastatic Biliary Tract Cancer",[442,462],"Ipilimumab",{"nctId":464,"briefTitle":465,"status":429,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":471},"NCT05116917","Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.",[37],"2023-10-19","2021-11-05",19,[23],[442,462,472],"Influenza vaccine",{"nctId":474,"briefTitle":475,"status":429,"phases":476,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":481},"NCT04258150","Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer",[37],"2021-11-23","2020-04-16",26,[23],[442,462,482],"Tocilizumab",{"nctId":484,"briefTitle":485,"status":58,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT04247165","Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.",[36,37],"2024-05-24","2024-12-05","2020-06-02",55,[492],"Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer",[494,495,442,462],"Gemcitabine","Nab-paclitaxel",{"trials":497,"activeCount":11},[],{"trials":499,"activeCount":11},[],{"trials":501,"activeCount":11},[],{"intervention":462,"totalTrials":30,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":505,"activeCount":11},[],{"trials":507,"activeCount":11},[],{"trials":509,"activeCount":11},[510,514,518,522],{"nctId":451,"briefTitle":452,"status":58,"phases":511,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":512,"interventions":513},[37],[459,460],[442,462],{"nctId":464,"briefTitle":465,"status":429,"phases":515,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":516,"interventions":517},[37],[23],[442,462,472],{"nctId":474,"briefTitle":475,"status":429,"phases":519,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":520,"interventions":521},[37],[23],[442,462,482],{"nctId":484,"briefTitle":485,"status":58,"phases":523,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":524,"interventions":525},[36,37],[492],[494,495,442,462],{"trials":527,"activeCount":11},[],{"trials":529,"activeCount":11},[],{"trials":531,"activeCount":11},[],{"intervention":494,"totalTrials":30,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":575,"PHASE4":577,"NA":579},{"trials":535,"activeCount":11},[],{"trials":537,"activeCount":11},[],{"trials":539,"activeCount":11},[540,544,556,566],{"nctId":484,"briefTitle":485,"status":58,"phases":541,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":542,"interventions":543},[36,37],[492],[494,495,442,462],{"nctId":545,"briefTitle":546,"status":58,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":554},"NCT02767557","Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients",[37],"2021-08-12","2023-01-01","2017-01-26",147,[553],"Unresectable Pancreatic Carcinoma",[482,494,555],"nab-Paclitaxel",{"nctId":557,"briefTitle":558,"status":58,"phases":559,"completion":560,"start":561,"enrollment":337,"conditions":562,"interventions":563},"NCT00115635","Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer",[36,37],"2007-07","2005-03",[21],[564,565],"docetaxel","gemcitabine",{"nctId":567,"briefTitle":568,"status":429,"phases":569,"primaryCompletion":570,"completion":570,"start":456,"enrollment":571,"conditions":572,"interventions":573},"NCT02767752","Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer",[37],"2018-07",21,[23],[494,574],"Capecitabine",{"trials":576,"activeCount":11},[],{"trials":578,"activeCount":11},[],{"trials":580,"activeCount":11},[],{"intervention":495,"totalTrials":146,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":597,"PHASE4":599,"NA":601},{"trials":584,"activeCount":11},[],{"trials":586,"activeCount":11},[],{"trials":588,"activeCount":11},[589,593],{"nctId":484,"briefTitle":485,"status":58,"phases":590,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":591,"interventions":592},[36,37],[492],[494,495,442,462],{"nctId":545,"briefTitle":546,"status":58,"phases":594,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":595,"interventions":596},[37],[553],[482,494,555],{"trials":598,"activeCount":11},[],{"trials":600,"activeCount":11},[],{"trials":602,"activeCount":11},[],{"intervention":604,"totalTrials":170,"cells":605},"Everolimus",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":607,"activeCount":11},[],{"trials":609,"activeCount":11},[],{"trials":611,"activeCount":11},[612],{"nctId":613,"briefTitle":614,"status":58,"phases":615,"primaryCompletion":616,"completion":84,"start":617,"enrollment":618,"conditions":619,"interventions":621},"NCT01387880","Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer",[37],"2011-11","2010-01",100,[620],"Metastatic Colorectal Cancer",[604,604],{"trials":623,"activeCount":11},[],{"trials":625,"activeCount":11},[],{"trials":627,"activeCount":11},[],{"intervention":629,"totalTrials":170,"cells":630},"A combination of fosfomycin, metronidazole and GM-CSF i.p.",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":646,"PHASE4":648,"NA":650},{"trials":632,"activeCount":11},[],{"trials":634,"activeCount":11},[],{"trials":636,"activeCount":11},[637],{"nctId":638,"briefTitle":639,"status":58,"phases":640,"primaryCompletion":641,"completion":641,"start":642,"enrollment":62,"conditions":643,"interventions":645},"NCT03046758","The Safety and Pharmacokinetics of Intraperitoneal Administration in Patients Undergoing Appendectomy for Uncomplicated Appendicitis",[37],"2017-12-07","2017-02-24",[644],"Appendicitis",[629],{"trials":647,"activeCount":11},[],{"trials":649,"activeCount":11},[],{"trials":651,"activeCount":11},[],{"intervention":653,"totalTrials":170,"cells":654},"Calcium electroporation",{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":659,"PHASE3":673,"PHASE4":675,"NA":677},{"trials":656,"activeCount":11},[],{"trials":658,"activeCount":11},[],{"trials":660,"activeCount":11},[661],{"nctId":662,"briefTitle":663,"status":58,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT01941901","Calcium Electroporation for Treatment of Cutaneous Metastases",[37],"2016-09","2017-01-23","2013-09",7,[670],"Cutaneous Metastases",[653,672],"Electrochemotherapy with bleomycin",{"trials":674,"activeCount":11},[],{"trials":676,"activeCount":11},[],{"trials":678,"activeCount":11},[],{"intervention":672,"totalTrials":170,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":682,"activeCount":11},[],{"trials":684,"activeCount":11},[],{"trials":686,"activeCount":11},[687],{"nctId":662,"briefTitle":663,"status":58,"phases":688,"primaryCompletion":665,"completion":666,"start":667,"enrollment":668,"conditions":689,"interventions":690},[37],[670],[653,672],{"trials":692,"activeCount":11},[],{"trials":694,"activeCount":11},[],{"trials":696,"activeCount":11},[],{"intervention":472,"totalTrials":170,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":709,"PHASE4":711,"NA":713},{"trials":700,"activeCount":11},[],{"trials":702,"activeCount":11},[],{"trials":704,"activeCount":11},[705],{"nctId":464,"briefTitle":465,"status":429,"phases":706,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":707,"interventions":708},[37],[23],[442,462,472],{"trials":710,"activeCount":11},[],{"trials":712,"activeCount":11},[],{"trials":714,"activeCount":11},[],{"intervention":716,"totalTrials":170,"cells":717},"pegylated liposomal doxorubicin",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":719,"activeCount":11},[],{"trials":721,"activeCount":11},[],{"trials":723,"activeCount":11},[724],{"nctId":725,"briefTitle":726,"status":58,"phases":727,"primaryCompletion":728,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":734},"NCT01206881","Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +\u002F- Trastuzumab Followed by Docetaxel in Breast Cancer",[37],"2011-05","2011-06","2009-03",45,[733],"Breast Cancer",[716],{"trials":736,"activeCount":11},[],{"trials":738,"activeCount":11},[],{"trials":740,"activeCount":11},[],{"intervention":742,"totalTrials":170,"cells":743},"peptides derived from antiapoptotic proteins",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":745,"activeCount":11},[],{"trials":747,"activeCount":11},[],{"trials":749,"activeCount":11},[750],{"nctId":751,"briefTitle":752,"status":58,"phases":753,"primaryCompletion":754,"completion":755,"start":756,"enrollment":287,"conditions":757,"interventions":759},"NCT01272466","Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma",[36,37],"2012-02","2015-01-01","2010-02",[758],"Relapsed Multiple Myeloma",[742],{"trials":761,"activeCount":11},[],{"trials":763,"activeCount":11},[],{"trials":765,"activeCount":11},[],{"intervention":767,"totalTrials":170,"cells":768},"tumor antigen loaded autologous dendritic cells",{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":770,"activeCount":11},[],{"trials":772,"activeCount":11},[],{"trials":774,"activeCount":11},[775],{"nctId":776,"briefTitle":777,"status":58,"phases":778,"primaryCompletion":779,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT00197912","Dendritic Cell Based Therapy of Malignant Melanoma",[36,37],"2010-04","2004-09",25,[783],"Advanced Melanoma",[767],{"trials":786,"activeCount":11},[],{"trials":788,"activeCount":11},[],{"trials":790,"activeCount":11},[],{"intervention":564,"totalTrials":170,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":794,"activeCount":11},[],{"trials":796,"activeCount":11},[],{"trials":798,"activeCount":11},[799],{"nctId":557,"briefTitle":558,"status":58,"phases":800,"completion":560,"start":561,"enrollment":337,"conditions":801,"interventions":802},[36,37],[21],[564,565],{"trials":804,"activeCount":11},[],{"trials":806,"activeCount":11},[],{"trials":808,"activeCount":11},[],{"intervention":810,"totalTrials":170,"cells":811},"Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":813,"activeCount":11},[],{"trials":815,"activeCount":11},[],{"trials":817,"activeCount":11},[818],{"nctId":819,"briefTitle":820,"status":58,"phases":821,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":827},"NCT03435900","Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis",[37],"2018-07-17","2018-02-14",13,[826],"Appendicitis Perforated",[810,828],"Standard antibiotics intravenously",{"trials":830,"activeCount":11},[],{"trials":832,"activeCount":11},[],{"trials":834,"activeCount":11},[],{"intervention":828,"totalTrials":170,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":838,"activeCount":11},[],{"trials":840,"activeCount":11},[],{"trials":842,"activeCount":11},[843],{"nctId":819,"briefTitle":820,"status":58,"phases":844,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":845,"interventions":846},[37],[826],[810,828],{"trials":848,"activeCount":11},[],{"trials":850,"activeCount":11},[],{"trials":852,"activeCount":11},[],{"intervention":854,"totalTrials":170,"cells":855},"Melatonin, N-acetyl-5-methoxytryptamine",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":857,"activeCount":11},[],{"trials":859,"activeCount":11},[],{"trials":861,"activeCount":11},[862],{"nctId":863,"briefTitle":864,"status":58,"phases":865,"primaryCompletion":363,"completion":866,"start":867,"enrollment":433,"conditions":868,"interventions":871},"NCT01172171","The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction",[37],"2016-12","2013-06",[869,870],"Acute Myocardial Infarction","Ischemia-reperfusion Injury",[854,872],"Isotonic saline, Natrium chloride",{"trials":874,"activeCount":11},[],{"trials":876,"activeCount":11},[],{"trials":878,"activeCount":11},[],{"intervention":872,"totalTrials":170,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":882,"activeCount":11},[],{"trials":884,"activeCount":11},[],{"trials":886,"activeCount":11},[887],{"nctId":863,"briefTitle":864,"status":58,"phases":888,"primaryCompletion":363,"completion":866,"start":867,"enrollment":433,"conditions":889,"interventions":890},[37],[869,870],[854,872],{"trials":892,"activeCount":11},[],{"trials":894,"activeCount":11},[],{"trials":896,"activeCount":11},[],{"intervention":898,"totalTrials":170,"cells":899},"Belinostat and Erlotinib",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":915,"PHASE4":917,"NA":919},{"trials":901,"activeCount":11},[],{"trials":903,"activeCount":11},[],{"trials":905,"activeCount":11},[906],{"nctId":907,"briefTitle":908,"status":429,"phases":909,"primaryCompletion":910,"completion":910,"start":911,"enrollment":19,"conditions":912,"interventions":914},"NCT01188707","A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer",[36,37],"2011-06-30","2010-10-01",[913],"Non Small Cell Lung Cancer",[898],{"trials":916,"activeCount":11},[],{"trials":918,"activeCount":11},[],{"trials":920,"activeCount":11},[],{"intervention":574,"totalTrials":170,"cells":922},{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":924,"activeCount":11},[],{"trials":926,"activeCount":11},[],{"trials":928,"activeCount":11},[929],{"nctId":567,"briefTitle":568,"status":429,"phases":930,"primaryCompletion":570,"completion":570,"start":456,"enrollment":571,"conditions":931,"interventions":932},[37],[23],[494,574],{"trials":934,"activeCount":11},[],{"trials":936,"activeCount":11},[],{"trials":938,"activeCount":11},[],{"intervention":940,"totalTrials":170,"cells":941},"Paclitaxel, Carboplatin and Vorinostat",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":943,"activeCount":11},[],{"trials":945,"activeCount":11},[],{"trials":947,"activeCount":11},[948],{"nctId":949,"briefTitle":950,"status":185,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":957},"NCT00772798","A Phase I\u002FII Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer",[37],"2009-06","2007-06",70,[956],"Ovarian Cancer",[940],{"trials":959,"activeCount":11},[],{"trials":961,"activeCount":11},[],{"trials":963,"activeCount":11},[],{"intervention":965,"totalTrials":170,"cells":966},"Allogeneic Tumour Lysate",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":968,"activeCount":11},[],{"trials":970,"activeCount":11},[],{"trials":972,"activeCount":11},[973],{"nctId":974,"briefTitle":975,"status":58,"phases":976,"primaryCompletion":977,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":981},"NCT00442754","Dendritic Cells in Lung Cancer",[37],"2009-11","2006-12",50,[913],[965],{"trials":983,"activeCount":11},[],{"trials":985,"activeCount":11},[],{"trials":987,"activeCount":11},[],{"intervention":989,"totalTrials":170,"cells":990},"Onco-peptide loaded autologous dendritic cells",{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":992,"activeCount":11},[],{"trials":994,"activeCount":11},[],{"trials":996,"activeCount":11},[997],{"nctId":998,"briefTitle":999,"status":429,"phases":1000,"start":780,"enrollment":287,"conditions":1001,"interventions":1003},"NCT00197925","Dendritic Cell Based Therapy of Metastatic Breast Cancer",[36,37],[1002],"Metastatic Breast Cancer",[989],{"trials":1005,"activeCount":11},[],{"trials":1007,"activeCount":11},[],{"trials":1009,"activeCount":11},[],{"intervention":1011,"totalTrials":170,"cells":1012},"Rosiglitazone",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1014,"activeCount":11},[],{"trials":1016,"activeCount":11},[],{"trials":1018,"activeCount":11},[1019],{"nctId":1020,"briefTitle":1021,"status":185,"phases":1022,"completion":953,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT00309660","Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis",[36,37],"2005-11",20,[1026],"Ulcerative Colitis",[1011],{"trials":1029,"activeCount":11},[],{"trials":1031,"activeCount":11},[],{"trials":1033,"activeCount":11},[],{"intervention":1035,"totalTrials":170,"cells":1036},"EVAX-01-CAF09b",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1054,"PHASE4":1056,"NA":1058},{"trials":1038,"activeCount":11},[],{"trials":1040,"activeCount":11},[],{"trials":1042,"activeCount":11},[1043],{"nctId":1044,"briefTitle":1045,"status":185,"phases":1046,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":139,"conditions":1049,"interventions":1053},"NCT03715985","Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)",[36,37],"2022-12-01","2019-01-28",[1050,1051,1052],"Malignant Melanoma, Metastatic","Non Small Cell Lung Cancer Metastatic","Bladder Urothelial Carcinoma, Metastatic",[1035],{"trials":1055,"activeCount":11},[],{"trials":1057,"activeCount":11},[],{"trials":1059,"activeCount":11},[],{"intervention":1061,"totalTrials":170,"cells":1062},"Bcl-Xl_42-CAF09b vaccine",{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1064,"activeCount":11},[],{"trials":1066,"activeCount":11},[1067],{"nctId":1068,"briefTitle":1069,"status":58,"phases":1070,"primaryCompletion":1071,"completion":1071,"start":1072,"enrollment":1024,"conditions":1073,"interventions":1074},"NCT03412786","Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases",[36],"2021-12-08","2018-05-01",[21],[1061],{"trials":1076,"activeCount":11},[],{"trials":1078,"activeCount":11},[],{"trials":1080,"activeCount":11},[],{"trials":1082,"activeCount":11},[],{"intervention":1084,"totalTrials":170,"cells":1085},"Vaccine consisting of a peptide derived from the protein IDO",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1099,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1087,"activeCount":11},[],{"trials":1089,"activeCount":11},[1090],{"nctId":1091,"briefTitle":1092,"status":58,"phases":1093,"primaryCompletion":364,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT02077114","Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma",[36],"2014-02",10,[1097],"Malignant Melanoma With Metastasis",[1084],{"trials":1100,"activeCount":11},[],{"trials":1102,"activeCount":11},[],{"trials":1104,"activeCount":11},[],{"trials":1106,"activeCount":11},[],{"intervention":1108,"totalTrials":170,"cells":1109},"ARG1-18,19,20",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1111,"activeCount":11},[],{"trials":1113,"activeCount":11},[1114],{"nctId":1115,"briefTitle":1116,"status":58,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":824,"conditions":1120,"interventions":1126},"NCT03689192","Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors",[36],"2022-01-19","2018-12-17",[913,1121,1122,956,1123,733,1124,1125],"Urothelial Carcinoma","Malignant Melanoma","Colorectal Cancer","Squamous Cell Carcinoma of the Head and Neck","Metastatic Cancer",[1108],{"trials":1128,"activeCount":11},[],{"trials":1130,"activeCount":11},[],{"trials":1132,"activeCount":11},[],{"trials":1134,"activeCount":11},[],{"intervention":1136,"totalTrials":170,"cells":1137},"Calcium chloride",{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1149,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1139,"activeCount":11},[],{"trials":1141,"activeCount":11},[1142],{"nctId":1143,"briefTitle":1144,"status":58,"phases":1145,"primaryCompletion":1072,"completion":1072,"start":93,"enrollment":668,"conditions":1146,"interventions":1148},"NCT01941914","Calcium Electroporation for the Treatment of Keloids",[36],[1147],"Keloid",[1136],{"trials":1150,"activeCount":11},[],{"trials":1152,"activeCount":11},[],{"trials":1154,"activeCount":11},[],{"trials":1156,"activeCount":11},[],{"intervention":1158,"totalTrials":170,"cells":1159},"Cilostazol",{"EARLY_PHASE1":1160,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1161,"activeCount":11},[1162],{"nctId":1163,"briefTitle":1164,"status":58,"phases":1165,"primaryCompletion":1166,"completion":1166,"start":364,"enrollment":1167,"conditions":1168,"interventions":1170},"NCT02253004","Induction of Migraine Aura With Cilostazol",[35],"2015-08",16,[1169,15],"Migraine With Aura",[1158],{"trials":1172,"activeCount":11},[],{"trials":1174,"activeCount":11},[],{"trials":1176,"activeCount":11},[],{"trials":1178,"activeCount":11},[],{"trials":1180,"activeCount":11},[],{"intervention":1182,"totalTrials":170,"cells":1183},"Sildenafil",{"EARLY_PHASE1":1184,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1185,"activeCount":11},[1186],{"nctId":1187,"briefTitle":1188,"status":58,"phases":1189,"primaryCompletion":1190,"completion":1191,"start":1192,"enrollment":1167,"conditions":1193,"interventions":1194},"NCT02795351","Induction of Migraine Aura With Sildenafil",[35],"2021-02","2021-08","2015-06",[1169],[1182],{"trials":1196,"activeCount":11},[],{"trials":1198,"activeCount":11},[],{"trials":1200,"activeCount":11},[],{"trials":1202,"activeCount":11},[],{"trials":1204,"activeCount":11},[],{"intervention":482,"totalTrials":9,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1208,"activeCount":11},[],{"trials":1210,"activeCount":11},[],{"trials":1212,"activeCount":11},[1213,1217],{"nctId":474,"briefTitle":475,"status":429,"phases":1214,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":1215,"interventions":1216},[37],[23],[442,462,482],{"nctId":545,"briefTitle":546,"status":58,"phases":1218,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":1219,"interventions":1220},[37],[553],[482,494,555],{"trials":1222,"activeCount":11},[],{"trials":1224,"activeCount":11},[],{"trials":1226,"activeCount":11},[1227],{"nctId":1228,"briefTitle":1229,"status":58,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":1024,"conditions":1233,"interventions":1237},"NCT03601611","Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms",[40],"2020-01-28","2019-01-01",[1234,1235,1236],"Solid Tumor","Colitis","Arthritis",[482],{"intervention":1239,"totalTrials":170,"cells":1240},"Tadalafil",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1242,"activeCount":11},[],{"trials":1244,"activeCount":11},[],{"trials":1246,"activeCount":11},[],{"trials":1248,"activeCount":11},[],{"trials":1250,"activeCount":11},[],{"trials":1252,"activeCount":11},[1253],{"nctId":1254,"briefTitle":1255,"status":310,"phases":1256,"primaryCompletion":756,"completion":756,"start":1257,"enrollment":11,"conditions":1258,"interventions":1260},"NCT00506701","Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension",[40],"2008-02",[1259],"Chronic Obstructive Lung Disease",[1239],{"intervention":1262,"totalTrials":170,"cells":1263},"Genotyping",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1265,"activeCount":11},[],{"trials":1267,"activeCount":11},[],{"trials":1269,"activeCount":11},[],{"trials":1271,"activeCount":11},[],{"trials":1273,"activeCount":11},[],{"trials":1275,"activeCount":11},[1276],{"nctId":1277,"briefTitle":1278,"status":58,"phases":1279,"primaryCompletion":136,"completion":136,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1285},"NCT01088100","Study of the Correlation Between Specific Genes and Cognitive Dysfunction After Surgery",[],"2010-08",279,[1283,1284],"Genotype","Cognitive Impairment",[1262],{"intervention":1287,"totalTrials":170,"cells":1288},"Levothyroxine",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1290,"activeCount":11},[],{"trials":1292,"activeCount":11},[],{"trials":1294,"activeCount":11},[],{"trials":1296,"activeCount":11},[],{"trials":1298,"activeCount":11},[],{"trials":1300,"activeCount":11},[1301],{"nctId":1302,"briefTitle":1303,"status":58,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1166,"enrollment":1306,"conditions":1307,"interventions":1309},"NCT02993562","Hypothyroidism, Metabolism and Food Intake",[],"2018-08-30",18,[1308],"Hypothyroidism",[1287],{"intervention":1311,"totalTrials":170,"cells":1312},"Glucose-dependent insulinotropic polypeptide",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1314,"activeCount":11},[],{"trials":1316,"activeCount":11},[],{"trials":1318,"activeCount":11},[],{"trials":1320,"activeCount":11},[],{"trials":1322,"activeCount":11},[],{"trials":1324,"activeCount":11},[1325],{"nctId":1326,"briefTitle":1327,"status":58,"phases":1328,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":1095,"conditions":1331,"interventions":1333},"NCT00716170","GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia",[],"2009-07","2008-07",[1332],"Type 2 Diabetes Mellitus",[1311],{"intervention":1335,"totalTrials":170,"cells":1336},"Changing dose of norepinephrine and blood pressure",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1338,"activeCount":11},[],{"trials":1340,"activeCount":11},[],{"trials":1342,"activeCount":11},[],{"trials":1344,"activeCount":11},[],{"trials":1346,"activeCount":11},[],{"trials":1348,"activeCount":11},[1349],{"nctId":1350,"briefTitle":1351,"status":58,"phases":1352,"completion":286,"start":1353,"enrollment":1095,"conditions":1354,"interventions":1356},"NCT00197886","Dose of Norepinephrine and the Concentration of L-Lactate in the Rectum and Stomach in Patients With Septic Shock.",[40],"2004-10",[1355],"Septic Shock",[1335],{"intervention":1358,"totalTrials":170,"cells":1359},"Somatropin",{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1361,"activeCount":11},[],{"trials":1363,"activeCount":11},[],{"trials":1365,"activeCount":11},[],{"trials":1367,"activeCount":11},[],{"trials":1369,"activeCount":11},[],{"trials":1371,"activeCount":11},[1372],{"nctId":1373,"briefTitle":1374,"status":185,"phases":1375,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":139,"conditions":1378,"interventions":1380},"NCT00969644","The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons",[40],"2010-03","2009-09",[1379],"Interaction Between the GH\u002FIGF-I System and the Immune-system",[1358,1381],"Pegvisomant",{"intervention":1381,"totalTrials":170,"cells":1383},{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1385,"activeCount":11},[],{"trials":1387,"activeCount":11},[],{"trials":1389,"activeCount":11},[],{"trials":1391,"activeCount":11},[],{"trials":1393,"activeCount":11},[],{"trials":1395,"activeCount":11},[1396],{"nctId":1373,"briefTitle":1374,"status":185,"phases":1397,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":139,"conditions":1398,"interventions":1399},[40],[1379],[1358,1381],{"intervention":1401,"totalTrials":170,"cells":1402},"Ropivacaine 0,5%",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1404,"activeCount":11},[],{"trials":1406,"activeCount":11},[],{"trials":1408,"activeCount":11},[],{"trials":1410,"activeCount":11},[],{"trials":1412,"activeCount":11},[],{"trials":1414,"activeCount":11},[1415],{"nctId":1416,"briefTitle":1417,"status":58,"phases":1418,"primaryCompletion":1376,"start":1419,"enrollment":1024,"conditions":1420,"interventions":1422},"NCT01024868","Assessment of Spread of Transversus Abdominis Plane Block",[],"2009-12",[1421],"Transversus Abdominis Plane Block",[1401],{"intervention":1424,"totalTrials":170,"cells":1425},"prophylactic stroke medication",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1427,"activeCount":11},[],{"trials":1429,"activeCount":11},[],{"trials":1431,"activeCount":11},[],{"trials":1433,"activeCount":11},[],{"trials":1435,"activeCount":11},[],{"trials":1437,"activeCount":11},[1438],{"nctId":1439,"briefTitle":1440,"status":185,"phases":1441,"primaryCompletion":1442,"completion":1443,"start":1444,"enrollment":1445,"conditions":1446,"interventions":1448},"NCT02731235","The Effect of Aerobic Exercise in Patients With Lacunar Stroke",[40],"2023-04","2024-03","2016-01",71,[1447],"Stroke, Lacunar",[1424],{"intervention":1450,"totalTrials":170,"cells":1451},"Levothyroxine treatment",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1453,"activeCount":11},[],{"trials":1455,"activeCount":11},[],{"trials":1457,"activeCount":11},[],{"trials":1459,"activeCount":11},[],{"trials":1461,"activeCount":11},[],{"trials":1463,"activeCount":11},[1464],{"nctId":1465,"briefTitle":1466,"status":58,"phases":1467,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1470,"conditions":1471,"interventions":1472},"NCT02891668","Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition",[],"2018-05-20","2015-05",42,[1308],[1450],{"intervention":1474,"totalTrials":170,"cells":1475},"E. Coli endotoxin",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1477,"activeCount":11},[],{"trials":1479,"activeCount":11},[],{"trials":1481,"activeCount":11},[],{"trials":1483,"activeCount":11},[],{"trials":1485,"activeCount":11},[],{"trials":1487,"activeCount":11},[1488],{"nctId":1489,"briefTitle":1490,"status":185,"phases":1491,"completion":1492,"start":1493,"conditions":1494,"interventions":1497},"NCT00197899","Low-Dose Endotoxemia and the Acute Phase Response",[40],"2005-01","2004-03",[1495,1496],"Endotoxemia","Sepsis",[1474],{"intervention":1499,"totalTrials":170,"cells":1500},"Analgesia",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1502,"activeCount":11},[],{"trials":1504,"activeCount":11},[],{"trials":1506,"activeCount":11},[],{"trials":1508,"activeCount":11},[],{"trials":1510,"activeCount":11},[],{"trials":1512,"activeCount":11},[1513],{"nctId":1514,"briefTitle":1515,"status":185,"phases":1516,"primaryCompletion":1517,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1524},"NCT01949922","Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter",[40],"2017-01","2018-01","2013-04",15,[1522,1523],"Fecal Incontinence","Anal Incontinence",[1499]]